Minnesota lawmakers propose controversial medically-assisted suicide bill
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide and Crisis Lifeline by dialing 988.
Minnesota state lawmakers are re-introducing a bill to legalize medically-assisted in dying, which is legal in 10 states and Washington, D.C.
The controversial bill would allow Minnesotans with terminal illnesses to self-administer a prescription medication that would kill them over a period of time — a practice that some argue is an ethical way to end suffering while others argue that it is a dangerous slippery slope for those in a vulnerable mental state.
"I'm proud to carry the Minnesota End-of-Life Options Act once again at the legislature. Over the past several years, I've heard countless stories from Minnesotans who want the ability to decide, with their doctors and loved ones, how they spend their final days," State Rep. Mike Freiberg said during a Thursday press conference, as FOX 9 Minneapolis first reported. "Their message is clear: They want compassion, autonomy and peace at the end of life."
The Minnesota legislation is modeled on Oregon's 1997 Death with Dignity Act.
"The person has to be an adult with a terminal illness and a prognosis of six months or less to live. They must be mentally capable of making decisions, and they must be able to self-ingest the medication," Freiberg said during the Thursday press conference.
He added that two medical clinicians must be able to confirm the person's diagnosis and consent, and the person undergoing medically-assisted death must also take a mental health examination.
The legislation is aimed at alleviating suffering for those with terminal, life-altering illnesses that impact physical and mental capability, such as ALS.
Tom Albin, who has ALS, spoke during the Thursday presser, as FOX 9 first reported.
"ALS is cruel. It will eventually trap me in a body that can't move."
"I am not suicidal, I love my life and the people in it," Albin said. "With my medical team, I've done things to extend my life with a feeding tube and a non-invasive ventilator. But ALS is cruel. It will eventually trap me in a body that can't move. But I'll be fully aware of it the whole time. And there's no escape."
Gina Schneider, regional campaign and advocacy manager for Compassion & Choices Action Network, told Fox News Digital that the organization is "so grateful for lead sponsor Rep. Mike Freiberg's dedication to bringing the compassionate option of medical aid in dying to Minnesota by reintroducing the End-of-Life Options Act"
"All Minnesotans deserve a full range of end-of-life care options," Schneider said. "We hope the legislature will honor the will of 73.2% of Minnesota voters who support this option for terminally ill adults in their final six months or less of life by getting HF 2998 to Governor Walz so he can make it law in 2025."
The Minnesota Alliance for Ethical Healthcare is taking a different stance, with spokesperson Nancy Utoft highlighting the potential dangers of such legislation in a news release shared with FOX 9.
"Physician-assisted suicide is often framed as a compassionate option, but the reality is that it deepens existing inequities in our healthcare system and places vulnerable individuals—especially those with disabilities, limited financial resources, and communities of color—at greater risk," Utoft said. "We should be saying yes to better care, not legalizing an option that pressures people into ending their lives prematurely."
Canada legalized medical assistance in dying (MAID) in 2017, and the nationwide law has prompted arguments about how medically-assisted suicide may prompt those suffering from mental health disorders to end their lives prematurely.
Minnesota state senators are expected to introduce the bill next.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
14 hours ago
- Hamilton Spectator
Georgetown and Caledon residents raise more than $37K in Walk to End ALS
The Georgetown and Caledon communities came together at Terra Cotta Conservation Area to join the ALS Canada Walk to End ALS. The walk raised critical funds for ALS Canada's programs and services, including access to community-based support, essential assistive equipment, and trusted information for people with ALS and their families. Kim Barry, Vice President of Community Services at ALS Canada, was at the walk and said that despite the cold weather, more than 200 people showed up to walk with ALS Canada. In the walk alone, they raised over $37,000. June is ALS Awareness Month, and ALS Canada will continue to host these types of walks throughout the month, with approximately 22 in total; this was one of the first. 'The community always rallies behind ALS. It's one of the diseases that people who've been affected by ALS, they support, whether they're individuals living with ALS now or if they lost a loved one 20 years ago,' shared Barry. With the money raised, ALS Canada has three mission areas: research, community services and equipment, and advocacy. They help people living with ALS in the community navigate the healthcare system and provide support to them. Their equipment program can provide 40 different items from their loan program that people can access based on their needs – everything from a walker to a hospital bed and anything in between that they would need in terms of the progression of this disease. ALS Canada can provide that to them at no cost. Barry shared that one of her favourite moments from the walk this year was seeing Team McKenzie Tulach Ard. 'Colin Mackenzie is an individual who's living with ALS. His team raised over $16,000 and Colin and his family were the ribbon-cutters of this year's walk,' said Barry. Barry shares that this isn't the first time this team has supported the fundraising, and she remarked that it's great how much they work to bring awareness to the disease. Barry has been with ALS Canada for 12 years and shared that she's come to know these families and their family stories over the years. 'People are really committed to ALS and they just keep coming back year after year. For some people, it's really about honouring the loss they have; they know that their loved one is no longer with them, but they still come out and represent their family and participate in the walk. It doesn't matter where people walk. Yes, the walk is a location, but some people want to walk in their backyard or their own community, it's really about just helping us bring the awareness to ALS,' said Barry. Barry shared that their goal at ALS Canada is to make sure people have the support they need while they're dealing with such a devastating illness, and she hopes more people understand that it can impact anyone. 'Getting involved in an event like the walk, it's one thing to be able to come as a family who's lost somebody, but encouraging our families to really come out and build connection. Truthfully, the walk is about community. And that is what we would want people to know,' said Barry. To participate in a walk or donate, visit Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Forbes
19 hours ago
- Forbes
USA Gymnastics President Li Li Leung To Step Down After Guiding Post-Nassar Reform
MINNEAPOLIS, MINNESOTA - JUNE 30: President and CEO of USA Gymnastics Li Li Leung (C-R) poses with ... More (L-R) Hezly Rivera, Joscelyn Roberson, Suni Lee, Simone Biles, Jade Carey, Jordan Chiles and Leanne Wong after they were selected for the 2024 U.S. Olympic Women's Gymnastics Team on Day Four of the 2024 U.S. Olympic Team Gymnastics Trials at Target Center on June 30, 2024 in Minneapolis, Minnesota. (Photo by) USA Gymnastics announced Thursday that President and CEO Li Li Leung will step down at the end of the year. This will mark the end of her nearly six-year tenure at the helm, during which Leung guided the organization after the Larry Nassar scandal. Hired in March 2019, the organization credits Leung's leadership for catalyzing a 'historic turnaround" and 'cultural transformation' within the sport. Leung helped the organization rebound from the blows dealt by the Nassar sexual abuse scandal, helping place athlete wellbeing and safety at the forefront. In December 2020, USA Gymnastics established its Athlete Bill of Rights, considered one of the 'first of its kind in sport,' demonstrating a commitment to 'a culture of athlete support and safety driving organizational decision-making." Leung's organization also introduced mental health visits to the National Team program Under the addition, USA Gymnastics now covers costs for regular visits to mental health providers for National Team athletes and coaches. Leung issued the following statement: 'The opportunity to lead USA Gymnastics has been the honor and privilege of a lifetime. Thanks to the dedication of the entire gymnastics community, we are now in an incredible position as we turn our attention to the L.A. Olympic Games. The last several months have been a time of great reflection, and I know that now is the right time to pass the torch to the next leader, with the sport and organization thriving. I wanted to ensure the board has the opportunity to conduct a thorough search and also give my successor a long runway into the 2028 Olympic Games. I'm going to take some time to reset before determining what is next, and I look forward to USA Gymnastics accomplishing great things in 2025 and beyond.' During her tenure, USA Gymnastics surged to success on the medal podium, most notably with 11 medals at the 2024 Olympic Games. In addition to her role with USA Gymnastics, Leung was the recipient of multiple honors in sport. In 2020, Leung was voted vice chair of the NGB Council of the U.S. Olympic sport governing bodies, and was elected to the Executive Committee of the International Gymnastics Federation (FIG) in 2021. Leung was named a Sports Business Journal 'Power Player' in 2020 and an SBJ Gamechanger in 2024. In 2023, she was recognized on the 2023 A100 list as one of the country's most impactful Asian Americans. She would later be named a 2025 WISE Woman of the Year. Chair of the USAG board of directors, Kathryn Carson, attested to the impact of Leung's leadership. 'Li Li was the right leader at the right time for USA Gymnastics and accomplished in six years what many thought was not possible," Carson said. 'Her deep passion for gymnastics and extraordinary dedication to leading transformation has positioned USA Gymnastics to move boldly toward LA28. With this strong foundation, we are confident we will identify a leader to build on Li Li's legacy.' With a home Olympic Games on the horizon in 2028, USA Gymnastics now commits to securing a replacement in the organization's pivotal quadrennium. The organization 'has engaged CAA Executive Search to lead the search for Leung's successor,' and intends to identify a new president and CEO prior to Leung's departure at 2025's close.
Yahoo
a day ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
